A clinical study to compare efficacy and safety of two different doses of CagriSema and semaglutide in participants with obesity with or without type 2 diabetes

Novo Nordisk0 个研究点目标入组 120 人开始时间: 2026年8月3日最近更新: 2026年8月3日

适应症

试验速览

暂无简介。

•Male or female (sex assigned at birth, inclusive of all gender identities).
•Age 18 years or above at the time of signing the informed consent.
•Body Mass Index (BMI) = 35.0 kg/m
•Participants without T2D (Sub-study 1): No history of T2D and glycated haemoglobin (HbA1c) < 6.5% (48 mmol/mol)
•Participants with T2D (Sub-study 2): A history of T2D and glycated haemoglobin (HbA1c) < 10% (< 86 mmol/mol). If a participant without a history of diabetes during the screening period receives an HbA1c result of 6.5% (48 mmol/mol) or higher, the investigator or the participant's healthcare provider must confirm the diagnosis of type 2 diabetes before the participant is randomised.

•A self-reported change in body weight > 5% within 90 days before screening, irrespective of medical records.
•Use of any glucagon like peptide-1 receptor agonist (GLP-1 RA), including medication with GLP-1 RA activity, or amylin analogues, including medication with amylin activity, within 6 months before screening

发起方